Trasis

What Trasis does

Trasis is a Belgian-headquartered, privately held designer and manufacturer of cassette-based radiochemistry synthesizers and integrated radiopharmacy workflow solutions, founded in 2004 by Jean-Luc Morelle and Gauthier Philippart. The company builds hardware platforms (AllinOne, AllinOne S, miniAllinOne, EasyOne), automated quality control systems (QC1), automated sterility testing (Sterinow), hospital dose dispensers (Unidose), radioprotection infrastructure (H2000/H600/H500 hotcells, shielded screens, shielded containers), single-use consumables, and a catalog of GMP-manufactured API precursors. The cassette-based architecture enables plug-and-play production of more than 40 PET tracers and theranostic radiometal-labeled compounds (68Ga, 177Lu, 99mTc, 89Zr, 64Cu, 90Y, 188Re, 203Pb) under GMP conditions, with the company's installed base supporting diagnosis or treatment of more than 4.5 million patients annually.

Trasis serves four primary customer segments: hospital nuclear medicine departments, academic and institutional research centers, pharmaceutical companies developing radiopharmaceuticals at scale, and radiopharmacy networks. Revenue is generated through hardware sales of synthesizers and supporting equipment, recurring consumables (single-use cassettes and reagents), professional services including training, custom development, and regulatory affairs support, and custom API precursor development and GMP manufacturing. Pricing is quote-based with multi-year contracts and no public price list. Go-to-market relies on direct enterprise field sales teams across offices in Belgium (Ans headquarters), the USA (Atlanta, established 2023), France (Grenoble area), and a China joint venture with Beijing PET Technology (established 2025), supplemented by active participation in major nuclear medicine conferences and a strong scientific publications library.

The company has grown from 50 employees in 2017 to 450 worldwide by 2025, completed two acquisitions (Eras Labo in 2023, the Flémalle pharmaceutical production site in 2026), and received the EY Entrepreneur of the Year 2025 award in Wallonia. Its product ecosystem is designed to standardize the complete radiopharmaceutical workflow — from synthesis through quality control, sterility testing, and patient dose dispensing — within a single vendor's proprietary cassette platform, creating a recurring consumable revenue model tied to the installed base.

Name

Trasis

Legal name

Trasis

Website

https://trasis.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Trasis is a Belgian-headquartered, privately held manufacturer of cassette-based radiochemistry synthesizers and integrated radiopharmacy workflow solutions — including QC, sterility testing, dose dispensing, and API precursors — serving hospitals, research centers, and pharmaceutical companies in nuclear medicine.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

akta.pro secondary industry

Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

Keywords

• Radiopharmaceutical equipment
• PET tracer synthesizers
• Radiopharmacy manufacturing
• Radiation shielding hotcells
• API precursor manufacturing

Headquarters

HQ city

Liège

HQ country

Belgium

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Equipment Sales: Sale of radiopharmaceutical synthesizers (AllinOne, miniAllinOne, EasyOne, AllinOne S), quality control systems (QC1), dose dispensers (Unidose), and radioprotection equipment (H2000, H600, H500 hotcells, mobile shielded screens, shielded containers).
2. Consumables: Ready-to-use cassettes and reagents for plug-and-play routine tracer production. Single-use cassettes prevent cross-contamination and ensure reproducible GMP-compliant productions.
3. API Precursors: Custom API precursors development and GMP manufacturing. Catalog includes peptides (DOTA-TATE, DOTA-TOC, NOTA-Octreotide), small molecules (TET, NVA, DMSA, DTPA, HMDP, etc.), organometallic compounds (CuMIBI), and chelators.
4. Services: Training, custom development, regulatory affairs support, customer support services, and chemical molecule development and manufacturing from synthesis to ready-to-use drug solutions.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Trasis designs, manufactures, and sells cassette-based radiochemistry synthesizers (AllinOne, AllinOne S, miniAllinOne, EasyOne) used by hospitals, research centers, and pharmaceutical companies to produce PET tracers and theranostic radiopharmaceuticals. The portfolio also includes the QC1 automated quality control system, Sterinow automated sterility testing, the Unidose hospital dose dispenser, a range of radioprotection hotcells and shielded containers, and a GMP-manufactured catalog of API precursors. Consumables (single-use cassettes and reagents), regulatory support, training, and custom molecule development round out an end-to-end radiopharmacy offering.

Product overview

Trasis offers an integrated portfolio of radiopharmacy solutions centered around cassette-based synthesizers for PET tracer production. The core product family includes AllinOne (versatile multi-tracer platform for research and production), AllinOne S (stackable high-throughput variant), miniAllinOne (compact routine production synthesizer for radiometals), and EasyOne (cost-effective radiometal labeling solution). These synthesizers are complemented by the EasyOne Cold kits for automated labelling and dispensing, QC1 for integrated quality control, and Sterinow for automated sterility testing. The Unidose hospital dispensing system handles patient dose preparation. Supporting infrastructure includes the H2000, H600, H500 hotcells, Mobile Shielded Screen, and Shielded containers for radioprotection. Ready-to-use consumables and spare parts support daily operations, while the API Precursors catalog provides chemical molecules for custom radiopharmaceutical development. The ecosystem enables hospitals, research centers, and pharmaceutical companies to develop, produce, and administer radiopharmaceuticals for diagnostic and therapeutic purposes.

Differentiator

Problem solved

Functional benefit

Brands

• AllinOne: PET Tracer Synthesizer - versatile, comprehensive synthesis solution for research labs and radiopharmacy networks
• AllinOne S
• miniAllinOne
• EasyOne
• Unidose
• QC1
• Sterinow
• H2000
• H600
• H500

Products and services

• AllinOne Synthesizer Universal cassette-based PET tracer synthesizer that operates in both research and production environments, supports more than 40 tracers, up to 4 HPLC columns and 15 radio detectors, and includes semi-preparative radio/UV HPLC plus reformulation capabilities for research labs and radiopharmacy networks.
• AllinOne S Synthesizer Stackable synthesizer with halved height allowing two units to stack inside the same synthesis cell for doubled production capacity, supporting up to 8 FDG batches without opening the hotcell for industrial radiotracer production.
• miniAllinOne Synthesizer Compact cassette-based synthesizer for GMP-compliant routine production of compounds labeled with radiometals such as 68Ga, 177Lu, 99mTc, 89Zr, 64Cu, 90Y, 188Re, and 203Pb, marketed as the theranostic synthesizer.
• EasyOne Synthesizer Most compact and user-friendly theragnostic synthesizer for routine production of tracers labeled with radioactive metals, compatible with all generators, cost-effective, and supporting more than 10 radio tracers for hospital radiometal labeling workflows.
• QC1 Quality Control System Automated radiopharmaceutical QC 'lab in a box' providing results in 30 minutes through a self-shielded, fully integrated system that runs all required tests on a single sample and is compatible with European and US pharmacopeia.
• Sterinow Automated Sterility Testing Cassette-based solution that automates preparation of sterility test samples using membrane filtration directly on site, simplifying a critical quality control step in radiopharmaceutical production, improving operator safety and cost efficiency, and licensed from CUP Contract Labs.
• Unidose Hospital Dispensing System Automated hospital dispensing system that prepares patient doses ready to be injected, dispensing one dose per few seconds with setup time under 3 minutes and filling accuracy around 20 microliters, reducing staff radiation exposure by up to 95% for nuclear medicine departments.
• EasyOne Cold Kits Labelling and Dispensing Automated solution for radiopharmaceutical preparation and dispensing offering automated generator elution, secured cold kits radiolabelling, and accurate automatic patient doses preparation with complete traceability; reduces operator finger radiation exposure by 75%.
• H2000 Hotcell Hotcell for chemistry and R&D projects designed to host a synthesis module and its accessories for production of radiopharmaceuticals, featuring an ISO-7 (Class-C) main enclosure with a compact design weighing only 2 tons.
• H600 Radiometals Hotcell Integrated hotcell for synthesis and dispensing of radiopharmaceutical products with minimal footprint, including molecules labeled with radio-metals such as 68Ga and 177Lu, featuring an ISO-7 shielded enclosure.
• H500 Compact Hotcell Compact hotcell for compact synthesizers, part of the full 68Ga solution with miniAllinOne or EasyOne synthesizer, designed to fit in narrow spaces.
• Mobile Shielded Screen Mobile radiation protection screen providing protection from dose preparation to the patient bedside, featuring a curved screen position, wide lead glass window, and ergonomic tray for safe dose administration.
• Shielded Container Final product shielding container with built-in activity sensor and 25mm-thick lead shielding for radio-protected vial storage and handling, allowing real-time measuring and monitoring of contained activity.
• API Precursors (Catalog and Custom GMP Manufacturing) Custom API precursors development and GMP manufacturing, from chemical synthesis of small molecules and peptides to production of ready-to-use drug solutions; catalog includes NOTA-Octreotide, CuMIBI, TET, DOTA-TATE, DOTA-TOC, DMSA, DTPA, DPD, EDTMP, HMDP, JK7-TMA, Mebrofenin, NVA, PTP, TATM, TSPP, and UCB-H.
• Ready-to-Use Consumables (Cassettes and Reagents) Comprehensive sets of cassettes and reagents produced under GMP and pharmaceutical-grade manufacturing requirements for plug-and-play operation; single-use cassettes prevent cross-contamination and ensure reproducible, GMP-compliant tracer productions.
• R&D Cassettes and Spare Parts R&D cassettes and individual cassette components that allow researchers to build custom cassettes suited to new tracers and implement novel chemistry runs, including custom-made cassettes for R&D.
• Professional Services (Training, Regulatory Affairs, Custom Development) Training, custom development, regulatory affairs support, customer support services, and chemical molecule development and manufacturing from synthesis to ready-to-use drug solutions, supporting customers through FDA Drug Master File submissions and Marketing Authorization applications.

Quantifiable outcome

• Reduces staff radiation exposure by up to 95%
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core and major.

• KU LeuvencoreStrategic or Co-development Partner · 11 June 2026Strengthened collaboration for targeted therapies. KU Leuven and Trasis are advancing next-generation targeted therapies through collaborative development in radiopharmaceutical research and production.
• Beijing PET TechnologycoreStrategic or Co-development Partner · 24 November 2025After over ten years of collaboration, Trasis formed a joint venture in China with Beijing PET Technology to strengthen local presence and expand access to advanced radiopharmaceutical solutions in China. The joint venture supports nuclear medicine growth in the Chinese market.
• CUP Contract LabscoreTechnology or Integration · 26 May 2025CUP Contract Labs granted exclusive license to Trasis for the advanced RADIOSTER cassette for automated sterility testing. The partnership enables Trasis to manufacture and distribute the RADIOSTER cassette solution, which automates sterility test sample preparation using membrane filtration directly on site, simplifying a critical quality control step in radiopharmaceutical production.
• SysarkmajorStrategic or Co-development Partner · 7 September 2023Trasis and Sysark joined forces to develop and distribute an automated dispenser for radiopharmaceuticals, combining Trasis's expertise in radiopharmacy equipment with Sysark's technology.
• Eras LabocoreStrategic or Co-development Partner · 2 February 2023Eras Labo joined the Trasis group, strengthening a strategic partnership that began three years earlier. Eras Labo brings expertise that complements Trasis's radiopharmacy solutions.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Others

• Lantheus Holdings: Radiopharmaceutical company focused on diagnostic and therapeutic agents. Representative of pharma end-customers who rely on Trasis equipment and consumables for production.
• Curium: World's largest nuclear medicine manufacturer producing PET and SPECT tracers globally. Functions as a major Trasis customer and integrator of its synthesis and QC platforms.

Broad incumbents

• Novartis (Advanced Accelerator Applications): Owner of AAA, a major radiopharmaceutical manufacturer and Trasis customer. While not a synthesizer competitor, it shapes upstream demand for radiopharma manufacturing equipment and APIs.
• Siemens Healthineers: Diversified medical imaging and diagnostics giant with adjacent PET imaging and radiopharma distribution (PETNET) operations. Competes indirectly through scale and integrated hospital relationships.

Direct peers

• Tema Sinergie: Italian supplier of radiopharmacy equipment including shielded cells, dispensing units, and synthesis modules. Directly comparable to Trasis's H-series hotcells and dose dispensers.
• GE HealthCare: Major medical device incumbent with the FASTlab cassette-based PET radiopharmacy synthesizer. Competes head-to-head with Trasis's AllinOne platform across hospital and pharma radiopharmacy customers.
• IBA (Ion Beam Applications): Belgian-headquartered provider of radiopharma solutions including the Synthera synthesizer. Closest geographic and product competitor to Trasis across synthesis and theranostics workflows.
• Scintomics: German radiopharmacy equipment specialist offering modular synthesis and cassette-based systems for PET and theranostic tracers. Directly comparable to Trasis's miniAllinOne and EasyOne.
• Comecer: Italian manufacturer of radiopharma equipment including shielding, synthesis modules, and dispensing systems. Overlaps with Trasis's hotcell and dose dispensing product lines.
• Eckert & Ziegler: German radiopharma services and equipment provider offering isotope production, radiopharmaceutical contract manufacturing, and lab equipment. Comparable as both a competitor and potential customer for Trasis precursor products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/trasis_pet

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trasis